GOSS Insider Trading Activity and SEC Form 4 Filings
GOSS insider trading summary
No open-market insider purchases or sales of Gossamer Bio, Inc. (GOSS) have been reported on SEC Form 4 in the past 12 months.
Latest GOSS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 19, 2025 | Sandra Milligan | Director | Buy | $50K (26,050 @ $1.92) |
| Jun 24, 2024 | Richard Aranda | Chief Medical Officer | Sell | $1K (1,908 @ $0.66) |
| Jun 21, 2024 | Faheem Hasnain | President & CEO | Buy | $250K (372,000 @ $0.67) |
| Jun 18, 2024 | Bryan Giraudo | COO/CFO | Buy | $59K (100,000 @ $0.59) |
| Jun 17, 2024 | Robert Paul Smith JR | Chief Commercial Officer | Buy | $15K (25,000 @ $0.60) |
| Mar 27, 2024 | Bryan Giraudo | COO/CFO | Sell | $7K (6,430 @ $1.16) |
| Mar 27, 2024 | Waage Christian | EVP, Tech Ops and Admin | Sell | $7K (6,430 @ $1.16) |
| Mar 27, 2024 | Faheem Hasnain | President & CEO | Sell | $27K (23,172 @ $1.16) |
| Mar 18, 2024 | Caryn Peterson | EVP, Regulatory Affairs | Sell | $5K (4,018 @ $1.33) |
| Mar 18, 2024 | Richard Aranda | Chief Medical Officer | Sell | $5K (4,018 @ $1.33) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.